SLIL Biomedical Corp.
Executive SummarySLIL Biomedical uses macrophage-based technology, combining sequential pathogenesis and synthetic chemistry, to develop therapeutics and diagnostics for diseases characterized by excessive cell proliferation. It was formed as the result of a merger between Sequential Medical Corp. and S'LIL Pharmaceuticals.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.